RCT of everolimus (rapamycin analog) with or without resistance training on bone formation in postmenopausal women

This randomized controlled trial enrolled postmenopausal women aged 60-75 years in a 1:1:1:1 design comparing oral everolimus 5 mg weekly, placebo weekly, everolimus plus resistance training (3 hours weekly), or placebo plus resistance training. The study measured bone formation, muscle function, bone and muscle protein turnover, and quality of life through imaging, biopsies, blood samples, and functional testing across 5-7 visits. No results are reported in the material provided.